Evidence-driven updates across biotech and AI

Articles, whitepapers and podcasts from our team and advisors.

December 9, 2025•External link

AI, LABI, and How we Invest: A Conversation with Neel Madhukar, PhD and Themasap Khan, PhD

Neel Madhukar, PhD, Chief Technology Officer of Luma Group’s proprietary AI model, LABI, discusses the genesis of the program and how it impacts day-to-day processes at Luma Group. Neel and Themasap discuss what we are building at Luma Group to change the game for biotech investing.

December 1, 2025

God Bless the Private Sector: How Private Funding is Bridging the Gap

Publicly funded basic research has long served as the foundation for breakthroughs. Yet proposed federal cuts, including reductions to the NSF and NIH, now threaten the early-stage research that the private sector traditionally does not fund. These changes have already stalled projects, eliminated jobs, and raised concerns about broader delays in scientific progress. At the same time, the United States faces intensifying competition with China, whose sustained investment in early-stage biotech has accelerated its global share of drug development. Although the US retains leadership in total R&D value, the trend signals growing vulnerability, one seemingly at odds with the administration’s broader “America First” agenda. The launch of the Genesis Mission, with its emphasis on AI-enabled science and biotechnology as a domain of national importance, hints at a potential restructuring rather than an abandonment of federal scientific priorities. In this environment, the private sector has emerged as an essential stabilizing force. As public funding recedes, venture capital and philanthropy must intervene earlier in the research lifecycle. This shift can bring rigorous private-sector diligence to basic science, likely focusing resources on fewer projects but with greater efficiency. To handle this complexity, biology-specific AI tools will shift from optional luxuries to indispensable necessities. Ultimately, this disruption offers a chance to modernize our infrastructure: building a resilient ecosystem capable of expanding, not just restoring, American scientific progress.

All Podcasts Whitepapers Articles

CEO Q&A: Curve Biosciences on Transforming Disease Detection Through Blood-Based Insights

At Luma Group, we partner with companies that are redefining the frontiers of healthcare through data, AI, and deep biological insight. Curve Biosciences is one such company, building a platform aimed at transforming how chronic diseases are detected and monitored. By turning a simple blood draw into a dynamic, organ-level view of disease biology, Curve is working to enable earlier intervention and more precise clinical decision-making. We spoke with the CEO of Curve Biosciences, Dr. Ritish Patnaik, to discuss the company’s Whole-Body Intelligence platform, recent clinical progress in cirrhosis, and how advances in AI and genomic modeling are shaping the future of disease monitoring.

One Pill, Multiple Pathways for Immunological Disease: Our Investment in Coultreon Bio

Over the past three decades, blockbuster biologics have transformed chronic inflammatory disease treatment, but their single-target approach has left many patients underserved and capped overall efficacy. A new wave of therapies, designed to modulate multiple inflammatory pathways simultaneously, aims to break this ceiling and redefine the standard of care.

December 1, 2025

Delivering on the Promise of Precision Medicine: Our Investment in Aeovian Pharmaceuticals

The promise of precision medicine has been to deliver safer, more effective treatments by tailoring them to the unique biology of disease. Historically, most treatments have only provided patients with symptomatic relief and rarely corrected the underlying disease biology, leaving them inadequately addressed. In 2003, the mapping of the human genome gave scientists a foundation to understand the link between genetic mutations and disease. Researchers have since continued to map other advanced “omics” such as proteomics and metabolomics. These high-resolution biological maps provide the tools to understand biology in finer resolution and to identify which genes and pathways result in disease. These mapping techniques allow researchers to develop drugs directly targeted to treat diseases and, in some cases, correct the underlying disease pathways.

October 1, 2025

The Next Frontier in Chronic Disease Monitoring: Our Investment in Curve Biosciences

Despite remarkable medical advances, real-time monitoring of organ health remains out of reach. Curve Biosciences is closing this gap with Whole-Body Intelligence™—a platform built on the world’s largest curated tissue atlas that maps how disease reshapes each organ at the molecular level. By tracing these precise signatures in blood, Curve delivers liquid biopsy tests that move beyond cancer to detect and monitor disease across the full spectrum of organ health. Its first product, a liver test, is already demonstrating superior accuracy and the potential to transform early detection and chronic disease management.

The New Era of Multi-OMICs Therapy: Our investment in Character Bio

Age-related macular degeneration (AMD) affects millions worldwide, leading to progressive vision loss and limited treatment options. Character Bio is changing that paradigm by combining an AI-driven multi-omics platform with the world’s richest AMD dataset to develop new precision therapies for these patients. At Luma, we invest in transformative companies, and Character Bio’s groundbreaking work promises to redefine the future of eye health.